Last checked at 28 Nov 2023 07:00
28 November 2023
Intuitive Investments Group plc
("IIG", or the "Company")
Update to the Board of Directors
Intuitive Investments Group plc (SFM: IIG), the closed-end investment company, is pleased to announce the appointment of Giles Willits to the Board of Directors as Chief Investment Officer, following the recent announcement of the Company's investment in Hui10 Inc. ("Hui10").
Giles has over 30 years' experience working in senior finance positions, including over 20 years in executive board positions, most recently as Group CFO at IG Design Group plc, an AIM50 company, and Entertainment One Ltd., a FTSE250 company. Giles was previously Director of Group Finance at J Sainsbury's plc, a FTSE100 company, and is a qualified Chartered Accountant. Specific to Hui10, Giles invested in Hui10 in 2018 and has been advising the business since his initial investment.
Giles is currently a Non-Executive Director of Shearwater Group plc and Acceler8 Ventures plc. Giles is also Treasurer of the University of Nottingham.
Giles holds 1,939,997 Ordinary Shares in IIG and is a participant in the Hui10 Share Incentive Growth Scheme.
Sir Nigel Rudd, Non-Executive Chairman at IIG, said: "I am delighted that Giles is joining IIG and look forward to working with him on the exciting opportunities that lie ahead."
Current Directorships | Previous Directorships within the last five years |
Acceler8 Ventures plc | IG Design Group plc |
Shearwater Group plc | IG Design Group UK Limited |
The Bear Club Limited |
-ENDS-
Enquiries:
Intuitive Investments Group plc | www.iigplc.com |
Sir Nigel Rudd, Non-Executive Chairman Robert Naylor, CEO
| Via FTI Consulting |
SP Angel Corporate Finance LLP - Financial Adviser | +44 (0) 20 3470 0470 |
Jeff Keating / David Hignell / Kasia Brzozowska
| |
FTI Consulting | +44 (0) 20 3727 1000 |
Jamie Ricketts / Valerija Cymbal / Jemima Gurney
| IIG@fticonsulting.com |
About Intuitive Investments Group plc
IIG is an investment company seeking to provide investors with exposure to a portfolio concentrating on fast growing and/or high potential Life Sciences and Technology businesses operating predominantly in the UK, continental Europe, the US and APAC, utilising the Board's experience to seek to generate capital growth over the long term for shareholders.
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ('MAR') which has been incorporated into UK law by the European Union (Withdrawal) Act 2018. Upon the publication of this announcement via Regulatory Information Service ('RIS'), this inside information is now considered to be in the public domain.